Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun 21:2:87-98.
doi: 10.2147/hmer.s6918.

Optimal management of hepatorenal syndrome in patients with cirrhosis

Paolo Angeli  1 , Filippo Morando  1
Affiliations
Review

Optimal management of hepatorenal syndrome in patients with cirrhosis

Paolo Angeli et al. Hepat Med. .

Abstract

Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output. There are 2 different types of HRS. Type 1 HRS, which is often precipitated by a bacterial infection, especially spontaneous bacterial peritonitis, is characterized by a rapidly progressive impairment of renal function. Despite its functional origin, the prognosis of type 1 HRS is very poor. Type 2 HRS is characterized by a stable or slowly progressive renal failure so that its main clinical consequence is not acute renal failure but refractory ascites and its impact on prognosis is less negative. New treatments (vasoconstrictors plus albumin, transjugular portosystemic shunt, and molecular adsorbent recirculating system), which were introduced in the past 10 years, are effective in improving renal function in patients with HRS. Among these treatments vasoconstrictors plus albumin can also improve survival in patients with type 1 HRS. Thus, this therapeutic approach has changed the management of this severe complication in patients with advanced cirrhosis.

Keywords: acute renal injury; albumin; ascites; bacterial infections; chronic kidney disease; cirrhosis; midodrine; renal failure; renal replacement therapy; spontaneous bacterial peritonitis; terlipressin; transjugular portosystemic shunt; vasoconstrictors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
New diagnostic criteria of hepatorenal syndrome.
Figure 2
Figure 2
Clinical types of hepatorenal syndrome.
Figure 3
Figure 3
Pathophysiology of progressive impairment of the effective circulating volume in patients with advanced cirrhosis. Abbreviations: PRA, plasma renin activity, NA, plasma level of noradrenaline, ADH, plasma level of antidiuretic hormone.
Figure 4
Figure 4
Key points in the management of type 1 hepatorenal syndrome.
Figure 5
Figure 5
Key points in the management of type 2 hepatorenal syndrome.
See this image and copyright information in PMC

References

    1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236. - PubMed
    1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157. - PubMed
    1. Kanel GC, Peters RL. Glomerular tubular reflux – a morphologic renal lesion associated with the hepatorenal syndrome. Hepatology. 1984;4:242–246. - PubMed
    1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164–176. - PubMed
    1. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut. 2007. (on line) - PMC - PubMed